Date:1/13/2011

e from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you nor is it considered to be investment advice. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

This material is based upon information that we consider to be reliable, but neither S&P nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. With respect to reports issued to clients in Japan and in the case of inconsistencies between the English and Japanese version of a report, the English version prevails. With respect to reports issued to clients in German and in the case of inconsistencies between the English and German version of a report, the English version prevails. Neither S&P nor its affiliates guarantee the accuracy of the translation. Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Neither S&P nor its affiliates are responsible for any errors or omissio
'/>"/>

SOURCE Standard & Poor's Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Atritech Announces Completion of a $22 Million Equity Financing
2. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
3. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
4. CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors
5. Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
6. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
7. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
8. Micromet Expands Committed Equity Financing Facility to $75 Million
9. ProUroCare Medical Inc. Announces Pricing of Equity Offering
10. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation